ProtoKinetix’ AAGP™ Shows Promise as a Tool in Diabetes Treatment / Cure

PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, January 12, 2010


Independent studies done by universities and corporations have illustrated a remarkable increase in the yield of viable stem cells after cryopreservation using AAGP™ in the freeze-thaw process. One future approach to increasing diabetics’ insulin production is related to an ability to convert their stem cells into islet cells for transplantation. The feasibility of this procedure is dependent upon the amount of functioning islet cells that can be derived from the patient’s stem cells. This is where AAGP™ can make a very beneficial contribution.

The Edmonton Protocol has successfully transplanted islet cells from donated pancreases into the liver and subsequently produced insulin in the patients. This protocol has been adopted by hospitals around the world, however, the lack of donors and the requirement for anti-rejection drugs severely restricts its use on a wide spread basis. The scientific community has been aggressively pursuing the ability to differentiate a person’s stem cells into islet cells. This achievement will provide a compatible source of islet cells that can be used in conjunction with the Edmonton Protocol. In order for this exciting new treatment to be both successful and economic on a universal scale, it is imperative that a very high recovery rate of islet cells is achieved. ProtoKinetix has demonstrated that it will be playing a pivotal role in the future treatment of diabetes.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.

For more detailed information, please visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO


Company Office:
Suite # 1500 ProtoKinetix Inc.
2225 Folkestone Way
West Vancouver, BC
V7S 2Y6

At ProtoKinetix:
Blair Henderson
604-926-6627
Email: info@protokinetix.com